Benjamin F. Edwards & Company’s CapForce IBD 50 ETF FFTY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-50
Closed -$1K 1855
2022
Q3
$1K Hold
50
﹤0.01% 1757
2022
Q2
$1K Buy
50
+10
+25% +$321 ﹤0.01% 1744
2022
Q1
$2K Buy
40
+30
+300% +$1.16K ﹤0.01% 1652
2021
Q4
$0 Hold
10
﹤0.01% 1724
2021
Q3
$0 Buy
+10
New +$467 ﹤0.01% 1720
2020
Q4
Sell
-1,062
Closed -$40K 1647
2020
Q3
$40K Sell
1,062
-195
-16% -$7.19K ﹤0.01% 948
2020
Q2
$43K Hold
1,257
﹤0.01% 917
2020
Q1
$35K Hold
1,257
﹤0.01% 926
2019
Q4
$44K Sell
1,257
-20
-2% -$677 ﹤0.01% 1003
2019
Q3
$41K Hold
1,277
﹤0.01% 989
2019
Q2
$44K Hold
1,277
﹤0.01% 940
2019
Q1
$43K Buy
1,277
+500
+64% +$15.7K ﹤0.01% 908
2018
Q4
$21K Sell
777
-11,285
-94% -$350K ﹤0.01% 1074
2018
Q3
$464K Sell
12,062
-164
-1% -$6.03K 0.04% 337
2018
Q2
$429K Buy
12,226
+12,126
+12,126% +$423K 0.04% 355
2018
Q1
$3K Buy
+100
New +$3.4K ﹤0.01% 1478
2017
Q4
Sell
-40
Closed -$1K 1592
2017
Q3
$1K Buy
+40
New +$1.18K ﹤0.01% 1497

Other funds holding FFTY

Benjamin F. Edwards & Company's FFTY Position: Q4 2022 in Review

Benjamin F. Edwards & Company sold out of CapForce IBD 50 ETF (FFTY) in Q4 2022, closing a stake of 50 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in FFTY in Q3 2017 and held it in 17 quarters. The position peaked at $464K in Q3 2018. 49 funds tracked by Wall St. Rank hold FFTY as of Q4 2022.

  • Benjamin F. Edwards & Company reported no remaining CapForce IBD 50 ETF position as of Q4 2022 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 50 CapForce IBD 50 ETF shares in Q4 2022, an estimated $1K.
  • Benjamin F. Edwards & Company first reported a position in CapForce IBD 50 ETF in Q3 2017 and held it in 17 quarters.
  • Benjamin F. Edwards & Company's CapForce IBD 50 ETF position peaked at $464K in Q3 2018.
  • 49 funds tracked by Wall St. Rank held CapForce IBD 50 ETF as of Q4 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2022, filed 7 Feb 2023.